A multicenter, randomized, double-blind, placebo-controlled, crossover phase II study of AXS-12 in patients with narcolepsy
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Reboxetine (Primary)
- Indications Narcolepsy
- Focus Therapeutic Use
- Acronyms CONCERT
- 30 Jan 2019 According to an Axsome Therapeutics media release, topline results from this trial are expected in the second quarter of 2019.
- 30 Jan 2019 Status changed from planning to recruiting, according to an Axsome Therapeutics media release.
- 27 Dec 2018 According to an Axsome Therapeutics media release, the company anticipates initiation of this study in January 2019, with topline results in the first half of 2019.